Yaky Yanay
2013
In 2013, Yaky Yanay earned a total compensation of $1.1M as Chief Financial Officer at Pluristem Therapeutics, a 15% increase compared to previous year.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Salary | $251,329 |
| Stock Awards | $770,000 |
| Other | $27,951 |
| Total | $1,124,280 |
Yanay received $770K in stock awards, accounting for 68% of the total pay in 2013.
Yanay also received $75K in bonus, $251.3K in salary and $28K in other compensation.
Rankings
In 2013, Yaky Yanay's compensation ranked 6,097th out of 12,286 executives tracked by ExecPay. In other words, Yanay earned more than 50.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,097 out of 12,286 | 50th |
Division Manufacturing | 2,126 out of 4,612 | 54th |
Major group Chemicals And Allied Products | 630 out of 1,462 | 57th |
Industry group Drugs | 454 out of 1,156 | 61st |
Industry Biological Products, Except Diagnostic Substances | 69 out of 196 | 65th |
Source: SEC filing on March 31, 2014.
Yanay's colleagues
We found one more compensation record of an executive who worked with Yaky Yanay at Pluristem Therapeutics in 2013.
2013
Zami Aberman
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019